Overview

A Study to Test Long-term Safety of BI 425809 in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Status:
Not yet recruiting

Trial end date:
2025-05-24

Target enrollment:

Participant gender:

Summary

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called BI 425809 in the long term. Participants take BI 425809 as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

BI 425809